Fez1/Lzts1 a new mitotic regulator implicated in cancer development
Tóm tắt
Considerable evidence has accumulated suggesting that cancer has genetic origin, based on the development of genomic alterations, such as deletions, mutations, and/or methylations in critical genes for homeostasis of cellular functions, including cell survival, DNA replication and cell cycle control. Mechanism controlling the precise timing and sequence of cell cycle events as well as checkpoints insuring fidelity of those events are key targets that when disrupted could result in tumorigenesis. Mitosis is the process by which a cell duplicates its genetic information (DNA), in order to generate two, identical, daughter cells. In addition each daughter cell must receive one centrosome and the appropriate complements of cytoplasm and organelles. This process is conventionally divided in to five distinct stages: prophase, prometaphase, metaphase, anaphase and telophase that correspond to a different morphology of the cell. The entry into mitosis (M) is under the control of the cyclin dependent kinase Cdk1. During G2, the kinases Wee1 and Myt1 phosphorylate Cdk1 at T14/Y15 residues, rendering it inactive. The transition from G2 to M is promoted by the activation of Cdk1 via dephosphorylation by the Cdk1 phosphatase Cdc25C. Activated Cdk1 complexes translocate into the nucleus during prophase where phosphorylate numerous substrates in order to enhance their activation as the cells progresses trough prophase, prometaphase, and metaphase. Recently we identified a new player: FEZ1/LZTS1 that contributes to the fine-tuning of the molecular events that determine progression through mitosis, and here will review its role in cancer development and in M phase regulation.
Tài liệu tham khảo
Ishii H, Baffa R, Numata S, Murakumo Y, Rattan S, Inoue H, Mori M, Fidanza V, Alder H, Croce CM: The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors. Proc Natl Acad Sci USA 1999, 96: 3928–3933. 10.1073/pnas.96.7.3928
Cabeza-Arvelaiz Y, Thompson TC, Sepulveda JL, Chinaul AC: LAPSER1: a novel candidate tumor suppressor gene from 10q24.3. Oncogene 2001, 20: 6707–6717. 10.1038/sj.onc.1204866
Teufel A, Weinmann A, Galle PR, Lohse AW: In silico characterization of LZTS3, a potential tumor suppressor. Oncol Rep 2005, 14: 547–551.
Thyssen G, Li TH, Lehmann L, Zhuo M, Sharma M, Sunz Z: LZTS2 is a novel beta-catenin-interacting protein and regulates the nuclear export of beta-catenin. Mol Cell Biol 2006, 26: 8857–8867. 10.1128/MCB.01031-06
Vecchione A, Ishii H, Shiao YH, Trapasso F, Rugge M, Alder H, Croce CM, Baffa R: Altered expression of Fez1 protein in gastric carcinoma. Clin Cancer Res 2001, 7: 1546–1552.
Vecchione A, Ishii H, Baldassarre G, Bassi P, Trapasso F, Alder H, Pagano F, Gomella LG, Croce CM, Baffa R: FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells. Am J Pathol 2002,160(4):1345–1352.
Vecchione A, Galetti TP, Gardiman M, Ishii H, Giarnieri E, Pagano F, Gomella LG, Croce CM, Baffa R: Collecting duct carcinoma of the kidney: an immunohistochemical study of 11 cases. BMC Urol 2004,9(4):11. 10.1186/1471-2490-4-11
Nonaka D, Fabbri A, Roz L, Mariani L, Vecchione A, Moore GW, Tavecchio L, Croce CM, Sozzi G: Reduced FEZ1/LZTS1 expression and outcome prediction in lung cancer. Cancer Res 2005, 65: 1207–1212. 10.1158/0008-5472.CAN-04-3461
Ono K, Uzawa K, Nakatsuru M, Shiiba M, Mochida Y, Tada A, Bukawa H, Miyakawa A, Yokoe H, Tanzawa H: Down-regulation of FEZ1/LZTS1 gene with frequent loss of heterozygosity in oral squamous cell carcinomas. Int J Oncol 2003, 23: 297–302.
Toyooka S, Fukuyama Y, Wistuba II, Tockman MS, Minna JD, Gazdar AF: Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures. Clin Cancer Res 2002, 8: 2292–2297.
Hawkins GA, Mychaleckyi JC, Zheng SL, Faith DA, Kelly B, Isaacs SD, Wiley KE, Chang BL, Ewing CM, Bujnovszky P, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J: Germline sequence variants of the LZTS1 gene are associated with prostate cancer risk. Cancer Genet Cytogenet 2002, 137: 1–7. 10.1016/S0165-4608(02)00549-6
Cabeza-Arvelaiz Y, Sepulveda JL, Lebovitz RM, Thompson TC, Chinault AC: Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22. Oncogene 2001, 20: 4169–4179. 10.1038/sj.onc.1204539
Ishii H, Vecchione A, Murakumo Y, Baldassarre G, Numata S, Trapasso F, Alder H, Baffa R, Croce CM: FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis. Proc Natl Acad Sci USA 2001, 98: 10374–10379. 10.1073/pnas.181222898
Vecchione A, Baldassarre G, Ishii H, Nicoloso MS, Belletti B, Petrocca F, Zanesi N, Fong LYY, Battista S, Guarnieri D, Baffa R, Alder H, Farber JL, Donovan PJ, Croce CM: Fez1/Lzts1 absence impairs Cdk1/Cdc25C interaction during mitosis and predisposes to cancer development. Cancer Cell 2007, 11: 275–289. 10.1016/j.ccr.2007.01.014
Rudolph J: Cdc25 Phosphatases: Structure, Specificity, and Mechanism. Biochemestry 2007, 46: 3595–3604. 10.1021/bi700026j
Chen F, Zhang Z, Bower J, Lu Y, Leonard SS, Ding M, Castranova V, Piwinca-Worms H, Shi X: Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 2002, 99: 1990–1995. 10.1073/pnas.032428899
Pines J: Mitosis: a matter of getting rid of the right protein at the right time. Trends Cell Biol 2006, 16: 55–63. 10.1016/j.tcb.2005.11.006
Nigg EA: Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2001, 2: 21–32. 10.1038/35048096
Smits VA, Medema RH: Checking out the G(2)/M transition. Biochim Biophys Acta 2001, 1519: 1–12.